Glycogen Storage Disease Type II Infantile Onset

1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Amicus Therapeutics
Amicus TherapeuticsPA - Philadelphia
1 program
1
Cipaglucosidase alfaPhase 31 trial
Active Trials
NCT04808505RecruitingEst. Jul 2027

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
Amicus TherapeuticsCipaglucosidase alfa

Clinical Trials (1)

NCT04808505Amicus TherapeuticsCipaglucosidase alfa

A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18

Start: Jul 2023Est. completion: Jul 2027
Phase 3Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials
1 companies competing in this space